78 results about "Brain metastasis" patented technology

The present disclosure relates generally to methods for treating or preventing central nervous system (CNS) metastases with a KRAS inhibitor, and more specifically to treating CNS metastases with a pyridopyrimidine derivative.

The invention discloses a multi-task lung cancer brain metastasis lifetime prediction method based on multi-modal data fusion, and relates to the field of medical image processing, and the method comprises the steps: obtaining non-small cell lung cancer CT image data, gene data and clinical data; performing focus segmentation on the non-small cell lung cancer CT image data; feature extraction is carried out based on the focus segmentation result, and radiomics features and depth image features are obtained; performing feature extraction on the gene data to obtain gene features; missing value deletion and numeralization preprocessing are carried out on the clinical data to obtain clinical features; local cross-modal attention fusion is carried out on the radiomics features and the depth image features; performing global cross-modal attention fusion on the preliminary mixed image features, the gene features and the clinical features to obtain original mixed features; and performing conditional guidance diffusion based on the original mixed features to obtain a lung cancer brain metastasis classification judgment result and a lifetime prediction risk. According to the invention, the lifetime prediction accuracy and stability can be improved.

The invention discloses a non-small cell lung cancer brain metastasis prediction method and device, and relates to the field of non-small cell lung cancer brain metastasis prediction. The method comprises the following steps: acquiring two-dimensional non-small cell lung cancer CT image data; inputting two-dimensional non-small cell lung cancer CT image data into the trained focus boundary segmentation model, and outputting a focus region segmentation image; the focus boundary segmentation model adopts an alternating network architecture based on a transformer block and a double-current Mangbar-transformer block; according to the focus area segmentation image, utilizing the trained non-small cell lung cancer brain metastasis prediction model to obtain a prediction result of whether the non-small cell lung cancer CT image data is a brain metastasis label or not according to the non-small cell lung cancer CT image data; the non-small cell lung cancer brain metastasis prediction model is a deep learning classification network of a heterogeneous axial cross attention mechanism with discrete wavelet transform processing. According to the method, the accuracy of predicting the brain metastasis result by using the non-small cell lung cancer CT image data can be improved.

The invention provides a lung cancer brain metastatic tumor preoperative risk prediction method based on a hybrid model, and relates to the field of medical image analysis and preoperative prediction, and the method comprises the steps of data preprocessing, model building, model training, model prediction and model evaluation. Wherein the construction of the model VKT is combined with KAN and Attention, and the model VKT is designed into a unique double-branch model, namely a ConvKan branch and an LGAttention branch. A ConvKan branch adopts a convolution BCBR module and a TCKan module, cross-channel information interaction is enhanced through parallel Token Kan and Channel Kan processing, and deep feature learning is promoted through residual connection. The LGAttention branch introduces local attention and global attention, so that the fine-grained structure and the overall semantics of the image can be effectively captured. By fusing the output features of the two branches, the VKT architecture not only retains the powerful capability of CNN in local feature extraction, but also gives full play to the advantages of Transform in global information modeling, and improves the interpretability of the model by means of KAN, thereby becoming an ideal choice for medical image analysis.

The invention provides a method and system for analyzing lung cancer brain metastasis organoid cell subpopulation and functional characteristics, and the method comprises a series of steps: data quality control, batch effect removal, cell grouping, copy number variation inference, quasi-time sequence analysis, function enrichment analysis, and drug sensitivity analysis before and after radiotherapy. Single cell transcriptome sequencing data obtained after organoid culture is subjected to personalized analysis, heterogeneity of tumor cells and sensitivity of the tumor cells to drugs after radiotherapy are described, and the characteristics of all cell subgroups in the lung cancer brain metastasis organoid and the effect of the cell subgroups in the tumor microenvironment can be accurately analyzed; powerful support is provided for mechanism research and precise medicine of lung cancer brain metastasis.

The invention discloses a human small cell lung cancer brain metastasis organoid culture medium and a culture method. According to the culture medium, an advanced DMEM / F12 culture medium is used as a basic culture medium, and the following components are added: 2 to 5 [mu] M of GlutaMax, 8 to 10 [mu] M of HEPES, 1 * to 2 * of B27, 500 [mu] M of SB202190, 5 to 10 [mu] M of Y-27632, 0.5 [mu] M of A83-01, 0.5 to 2 [mu] M of N-Acetyl-L-cysteine, 5 mM of Nicotinamide, 25 to 100 ng / ml of recombinant human FGF7, 100 to 500 ng / ml of recombinant human FGF10, 100 to 200 ng / ml of Human Noggin, 50 to 500 ng / ml of Human R-Spondin-1, 50 to 100 ng / ml of According to the culture method, TryPLE Express is used for dissociation, the time is short, the activity of dissociated single cells is high, and the success rate of organoid culture can be increased to the maximum extent. Meanwhile, by combining with a culture medium with an optimized formula proportion, formation and growth of brain metastatic organs of the human small cell lung cancer can be promoted, and the construction success rate is increased.

The invention discloses an application of a training immune agonist in preparation of a drug for sensitizing radiotherapy treatment of tumors, and researches show that the training immune agonist significantly activates immune response of a body by promoting expression of inflammatory cytokines, enhancing phagocytic ability of macrophages, recruiting immune cells and amplifying an immune activation effect, so that the immune response of the body is enhanced. The sensitivity of tumor cells to radiotherapy is improved, and a dual mechanism of'radiotherapy sensitization-immune synergy 'is formed, so that the bottleneck of the traditional radiotherapy curative effect is broken through, the local control rate of radiotherapy is improved, and the recurrence risk is reduced. Experiments prove that the training immune agonist combined with radiotherapy has a remarkable treatment effect on various highly invasive tumors (such as brain glioma and lung cancer brain metastasis) and common malignant tumors (such as colon cancer and lung cancer), and shows wide applicability. The invention provides a new combined therapy direction for tumor treatment, is expected to improve the prognosis of patients, prolong the lifetime and improve the life quality, and has important clinical transformation value.

A quinazoline derivative (represented by the formula (I)) salt's crystal form, a preparation method and application are provided; specifically, the hydrochloride crystal form A, B, C, D, F, H, I, Sulphate crystal form A, Maleate crystal form A, Succinate crystal form A, Adipate crystal form A, Glycolate crystal form A, Malate crystal form A, Fumarate Salt crystal form A, besylate crystal form A, B, C, benzoate crystal form A, hippurate crystal form A and oxalate crystal form A of the quinazoline derivative represented by formula (I). The salt crystal form provided by the present invention has good stability, which can be used in the treatment of non-small cell lung cancer brain metastasis, meningeal metastasis, primary brain cancer or glioma, etc., and has good bioavailability, which is of great significance for further research on the efficacy of such solid drugs.

The invention discloses an application of pegylated irinotecan in preparation of a medicine for preventing and / or treating triple-negative breast cancer brain metastasis diseases, which is shown by in-vivo imaging observation and lifetime observation of high, medium and low dose groups of pegylated irinotecan with a specific structure. The high-dose group, the medium-dose group and the low-dose group all have a definite anti-tumor effect, bioluminescence signal values are inhibited to different degrees, the lifetime is prolonged, and the lifetime of the high-dose group and the lifetime of the medium-dose group are remarkably longer than that of the NKTR-102 group.

The invention provides application of an arsenene nano preparation and / or beta-elemene in preparation of a product for treating brain tumors, and belongs to the technical field of biology. The arsenene nano preparation and / or beta-elemene are / is applied to brain glioma and lung cancer brain metastatic tumor model mice, so that tumor cells can be effectively killed, tumor metastasis can be inhibited, in-vivo immune response can be activated, maturation of dendritic cells can be promoted, NK cells and CD8 + T cells can be effectively activated, and the secretion amount of tumor suppression cell factors can be increased. Meanwhile, the beta-elemene effectively reduces cardiotoxicity caused by accumulation of the arsenene nano preparation in vivo.

The invention belongs to the field of biological medicines, and discloses an (R)-3-(1-([1, 1 '-biphenyl]-2-yl) ethyoxyl) pyridine-2-amine derivative as well as a synthesis method and application thereof. A compound with a structure as shown in a general formula I of the derivative or pharmaceutically acceptable salt, hydrate, solvate, polymorphic substance, tautomer, stereoisomer, isotope derivative or prodrug thereof has higher ROS1 or ALK protein kinase inhibitory activity; the compound has high anti-proliferative activity on human non-small cell lung cancer and solid tumors such as brain metastatic tumors, glioblastoma and breast cancer, and can be used for preparing drugs for treatment and / or prevention and / or delay and / or adjuvant treatment and / or treatment of tyrosine protein kinase, especially diseases mediated by ROS1 and ALK kinase and mutant kinase thereof.

The application belongs to the technical field of biology and particularly relates to application and a kit of CoL10A1. CoL10A1 is highly expressed in BC tissues and lowly expressed in normal tissues, CoL10A1 is highly expressed at mRNA and protein levels in BCBM tissues, therefore, application of a reagent for detecting CoL10A1 expression in preparation of a breast cancer brain metastasis diagnosis product is proposed, and the diagnosis product can also be used for diagnosing breast cancer.

The invention discloses treatment of EGFR mutation positive non-small cell lung cancer brain metastasis by administering an effective dose of an EGFR inhibitor. The EGFR inhibitor is N-(2-((2-(dimethylamine) ethyl) (methyl) amine)-4-methoxy-5-((4-(1-deuterated methyl-1H-indol-3-yl) pyrimidine-N '-2-yl) amine) phenyl) acrylamide mesylate.

Targeting Metabolic Pathways with MNK Inhibitors The invention belongs to the field of medicine and concerns the treatment of diseases related to aberrant upregulated de novo lipid biosynthesis using a MAPK interacting kinase (MNK) inhibitor, especially for the prophylaxis or treatment of breast cancers, prostate cancers, obesity, atherosclerosis, diabetes mellitus, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, chronic kidney disease, and neurological disorders. An aspect of the invention relates to the use of an MNK inhibitor designated (4-(3-((2- (dimethylamino)pyridin-4-yl)ethynyl)pyrazolo[1,5-a]pyrimidin-5-yl)phenyl)(morpholino) methanone, for the prophylaxis or treatment of triple-negative breast cancer and brain metastases therefrom.

The invention relates to application of GC7 in inhibiting proliferation or metastasis of cancer cells, in particular to inhibition of proliferation or metastasis of lung adenocarcinoma cells, and more particularly inhibition of proliferation or metastasis of the lung adenocarcinoma cells in the brain. On the basis, the GC7 can be developed into a medicine for inhibiting proliferation or migration of lung cancer cells, particularly a medicine for inhibiting brain metastasis of the lung cancer cells.

The application discloses application of tenapanol in preparation of a medicine for inhibiting tumor brain metastasis. The application targets neutrophils which are recruited in brain metastasis foci and promote tumor growth, screens out an inhibitor tenapanol for a neutrophil chemotactic receptor FPR2, inhibits the neutrophil recruitment to the brain and the subsequent promotion of tumor cell clonal growth by inhibiting the combination of the receptor and SAA1 which is specifically up-regulated in metastatic tumor cells, and thus the therapeutic effect of inhibiting the progression of intracranial lesions is achieved.

The invention discloses a substituted 2-amino-9-(3, 3-difluoropiperidine-4-yl)-7, 9-dihydro-8H-purine-8-ketone compound with a structural formula as shown in formula (I): (I) The substituted 2-amino-9-(3, 3-difluoropiperidine-4-yl)-7, 9-dihydro-8H-purine-8-ketone compound disclosed by the invention as well as a derivative and pharmaceutically acceptable salt thereof, and a preparation method of the substituted 2-amino-9-(3, 3-difluoropiperidine-4-yl)-7, 9-dihydro-8H-purine-8-ketone compound. The compound can be used as a protein kinase inhibitor drug to play a role, especially can inhibit protein expression induced by DNA-PK, and can be used for treating or preventing diseases related to abnormal protein kinase activity. The compound can be used for treating cancer, such as cancer, cancer accompanied with brain metastasis, cancer accompanied with meningeal metastasis, glioma, glioblastoma, diffuse endogenous bridge glioma (DIPG) and the like, and can be independently applied or combined with other treatment modes (such as radiation therapy or chemotherapy).

The invention discloses an application of a small molecule compound in preparation of a medicine for treating breast cancer. The MEN 10207 is screened through molecular docking analysis, and the capability of the MEN 10207 for remarkably inhibiting proliferation, migration and invasion of breast cancer cells is verified in MDA-MB-231 cells, so that the MEN 10207 has the potential of serving as a breast cancer brain metastasis inhibitor. A further research discovers that the MEN 10207 does not show obvious toxicity in the zebra fish and also shows good tolerance in a mouse intravenous injection test. After the MEN 10207 treats the zebra fish transplanted with the breast cancer cells, the survival and migration capabilities of the breast cancer cells in the zebra fish body are obviously reduced; after the MEN 10207 treats a mouse model with breast cancer brain metastasis, the colonization of breast cancer cells in the mouse brain is also obviously reduced, which proves that the MEN 10207 has the activity of resisting breast cancer brain metastasis in vivo.

Described herein are methods of treating a MTAP-null lung cancer in a patient comprising administering to the patient a PRMT5 inhibitor and an anti-PD1 antibody, optionally in combination with carboplatin and either paclitaxel or pemetrexed. Further described herein are methods of treating a MTAP-null cancer in a patient also suffering from brain metastases comprising administering to the patient a PRMT5 inhibitor.

The present invention relates to the field of tumor therapy and molecular immunology, relates to a pharmaceutical use of an anti-PD-1-anti-VEGFA bispecific antibody, and in particular, to a use of the anti-PD-1-anti-VEGFA bispecific antibody or a pharmaceutical combination of said antibody and a chemotherapy drug in the preparation of a drug for treating non-small cell lung cancer with brain metastases. The bispecific antibody can effectively treat non-small cell lung cancer with brain metastases, has high safety, and has good prospects of application.

The invention belongs to the field of tumor treatment and molecular immunology, and relates to medical application of an anti-VEGFA-anti-PD-1 bispecific antibody. Specifically, the invention relates to application of an anti-VEGFA-anti-PD-1 bispecific antibody or a pharmaceutical composition of the anti-VEGFA-anti-PD-1 bispecific antibody and chemotherapeutic drugs in preparation of drugs for treating non-small cell lung cancer brain metastasis. The bispecific antibody can effectively treat non-small cell lung cancer brain metastasis, is high in safety and has a good application prospect.

To provide methods for treating cancer.SOLUTION: Provided is a drug for inhibiting tumor growth or causing tumor regression in a subject with estrogen receptor alpha-positive breast cancer brain metastasis, the subject having one or more estrogen receptor alpha mutations selected from the group consisting of Y537S, Y537C, Y537N, D538G, and S463P. The drug comprises, as an active ingredient, a therapeutically effective amount of RAD1901 having a given structure, or a salt or solvate thereof, which is used in combination with palbociclib.SELECTED DRAWING: None

The present disclosure provides compositions and methods comprising amrannekast, or a pharmaceutically acceptable salt thereof, for the treatment and prevention of brain metastases. The present disclosure provides treatment and / or prevention of brain metastases in a subject suffering from ER + breast cancer within such compositions and methods.

The invention belongs to the technical field of biological medicine, and particularly relates to application of CST6 as a lung cancer brain metastasis early diagnosis marker. The core of the invention is to confirm that CST6 is used as a marker for early diagnosis and prediction of brain metastasis of lung cancer for the first time. In experimental verification, the CST6 protein expression quantity of the lung cancer cell strain H1975-BrM with high brain metastasis potential is remarkably higher than that of a common cell strain, an animal model further shows that overexpression of CST6 can promote formation of brain metastasis, and knock-down expression can inhibit metastasis capacity; clinical sample analysis shows that the serum CST6 concentration of brain metastasis patients is far higher than that of non-metastasis patients and healthy people, and the diagnostic value of CST6 is supported. In the aspect of diagnosis efficiency, the area under the ROC curve of the serum CST6 reaches 0.848, and high accuracy is shown. On the whole, the clinical blank is filled, and a reliable tool is provided for non-invasive lung cancer brain metastasis risk management.

The present disclosure provides methods for treating or inhibiting the growth of a tumor, wherein the method includes selecting a patient with lung cancer and brain metastasis in need thereof and administering to the patient a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor (e.g., cemiplimab or a bioequivalent thereof). In certain embodiments, the lung cancer is non-small cell lung cancer (NSCLC) and PD-L1 is expressed in ≥50% of tumor cells. In certain embodiments, the methods lead to improvements in functioning and quality of life.

This invention discloses a wasp venom peptide-M nanocomposite, its preparation method, and its applications, belonging to the field of medicinal chemistry. Using indocyanine green as a morphology mediator, this invention prepares an ultra-small particle size dendritic tetrasulfide by reacting it with triethylamine, hexadecyltrimethylammonium bromide, tetraethyl orthosilicate, and bis[3-(triethoxysilyl)propyl]tetrasulfide in water. Wasp venom peptide-M is then loaded onto this nanocomposite to obtain the wasp venom peptide-M nanocomposite. In vitro experiments have confirmed that this composite can significantly kill 4T1 breast cancer cells. Furthermore, thanks to its ultra-small particle size, it also exhibits good targeting and enrichment, significant anti-tumor efficacy, and excellent safety in a breast cancer brain metastasis model, providing a novel and efficient nanomedicine delivery system for brain tumor treatment and the development of related therapeutic drugs.

This invention belongs to the field of pharmaceutical formulation technology, specifically disclosing a gastrodin transdermal patch and its preparation method. The patch consists of a backing layer, a drug-containing matrix layer, and an anti-adhesive layer, using gastrodin as the active ingredient. It employs HP-β-CD inclusion technology, combined with an HPMC and PVP polymer backbone and an oleic acid-menthol composite transdermal enhancement system. The preparation utilizes solvent casting and low-temperature vacuum drying processes, which are mild and controllable. This invention effectively solves the problems of difficult transdermal absorption, easy recrystallization, and low bioavailability of gastrodin. The resulting patch has excellent adhesion, no skin irritation, high transdermal penetration, and good skin biocompatibility. It can efficiently cross the blood-brain barrier, regulate the neuroinflammatory microenvironment in the brain, significantly inhibit the colonization and progression of non-small cell lung cancer brain metastases, and strongly reverse tumor-related anxiety and depression-like mood disorders. It provides a novel drug delivery regimen with great clinical translational potential for the non-invasive synergistic treatment of brain tumors and their associated mood disorders.

The invention discloses a traditional Chinese medicine formula for treating lung adenocarcinoma brain metastasis, and relates to the technical field of treatment of lung adenocarcinoma brain metastasis. The traditional Chinese medicine formula comprises the following raw materials by weight: 10-12 g of gastrodia elata, 15-17 g of bighead atractylodes rhizome, 15-17 g of rhizoma smilacis glabrae, 44-46 g of oldenlandia diffusa, 15-17 g of rhizoma pinellinae praeparata, 21-23 g of plantain herb, 15-17 g of endothelium corneum gigeriae galli, 30-32 g of coix seeds, 25-27 g of edible tulip and 2-4 g of antelope horn powder. The traditional Chinese medicine formula for treating the brain metastasis of the lung adenocarcinoma has the effects of inhibiting the brain metastasis of the lung adenocarcinoma, dispersing blood stasis, detoxifying, softening hardness and dissipating binds, is low in treatment cost, convenient to take and small in limitation on patients, relieves pains of more patients suffering from the brain metastasis of the lung adenocarcinoma, prolongs life, improves life quality, can be prepared into a decoction for taking, and is suitable for clinical application. The composition can be processed into capsules, has more selections, and can provide convenience for patients.

The present invention relates to the treatment of cancer with metastases in the central nervous system (CNS), in particular in the brain, using the HER2 tyrosine kinase inhibitor zongertinib. Accordingly, compounds for use, methods of prevention and / or treatment and uses related to said treatment are herewith provided.

The utility model relates to the technical field of tumor cell metastasis models, in particular to a breast cancer circulating tumor cell remote metastasis model which comprises a base and a fixing rod, the fixing rod is fixedly connected to the base, the fixing rod is fixedly connected with a brain metastasis model, a placing component is installed on the brain metastasis model, and the placing component is fixedly connected with the brain metastasis model. The placing part comprises an inclined plate, a fixed plate, a movable plate, a pressed plate, a straight spring and a collecting box, the inclined plate is fixedly connected in the brain metastasis model, the clamping plate clamps small balls with different colors through the matching effect of the extrusion rod, the movable plate, the collecting box and other parts, the small balls can be taken out by pulling the clamping plate, and the small balls can be conveniently taken out. And residual water is left in the collecting box, so that the small balls can be quickly taken out, meanwhile, no water drips on the outer surface of the model, the situation that the transparency of the model is affected by water marks generated on the outer surface of the model due to water dripping is avoided, and the transparency of the organ model and the cleanliness of a placement environment are guaranteed.